Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
62.4
% (year-on-year change in operating profit)Wording
Conditional
How definitive the wording is.Results for this period
Third quarter2024年3月1日〜2024年11月30日ConsolidatedJapanese GAAPNet Sales89,236¥ millionYear on year +36.9%Progress 73.9%
Operating profit25,593¥ millionYear on year +62.4%Progress 80.9%
Ordinary income26,762¥ millionYear on year +25.5%Progress 84.9%
Net income attributable to owners of the parent19,708¥ millionYear on year +27.3%Progress 86.0%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share111円83銭
Financial position at period-end
Total assets176,684¥ million
of which net assets 119,168 ¥ millionEquity ratio 61.2%vs. prior year-end +2.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueSemiconductor and FPD Equipment Business ¥88,730 million (YoY +36.8%), Life Sciences Business ¥506 million (YoY +68.2%)
Segment profitSemiconductor and FPD Equipment Business ¥26,388 million (YoY +61.8%), Life Sciences Business ¥-53 million
Regional sales¥8,327 million, ¥11,979 million, ¥34,548 million, ¥5,981 million, ¥23,372 million, ¥5,026 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥120,784 million (YoY +29.5%)
Operating profit¥31,617 million (YoY +31.0%)
Ordinary income¥31,518 million (YoY +16.4%)
Net income¥22,916 million (YoY +17.1%)
Annual Dividend Forecast¥135 → ¥16（not_comparable）
Factors Behind Changes in Business Performance
半導体需要の回復と在庫の正常化が進む中、生成ＡＩ関連の先端半導体需要が中心となり、半導体需要の回復が進展した。中国では、自国のサプライチェーン強化を目指した半導体製造拠点の増強に伴い、中国向け装置需要が活発化した。
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 2 / Company name Nanoverse Technologies,Ltd., ジェノスタッフ株式会社 / Excluded Number of companies 0 / Company name Not disclosed
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥0 million / Extraordinary loss Loss on sale of fixed assets ¥0 million, Loss on Disposal of Fixed Assets ¥33 million
Depreciation and amortization¥2,094 million
Orders received and order backlogOrders received ¥81,562 million (YoY +135.7%) / Order backlog ¥62,652 million (YoY +102.4%)
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNo (no eligible attendees)
Issued Shares at Period-End176,400,000
Treasury Shares at Period-End42,860
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年3月1日〜2024年11月30日 |
| Net Sales | ¥89,236 million (YoY +36.9%) |
| Operating profit | ¥25,593 million (YoY +62.4%) |
| Ordinary income | ¥26,762 million (YoY +25.5%) |
| Profit attributable to owners of the parent | ¥19,708 million (YoY +27.3%) |
| Net income per share | 111円83銭 |
| Equity ratio | End of the current fiscal period 61.2 / End of previous period 59.1 |
| Total assets | ¥176,684 million |
| Net assets | ¥119,168 million |
| Full-year earnings forecast | Net Sales ¥120,784 million (YoY +29.5%) / Operating profit ¥31,617 million (YoY +31.0%) / Ordinary income ¥31,518 million (YoY +16.4%) / Net income ¥22,916 million (YoY +17.1%) |
| Annual Dividend Forecast | ¥135 → ¥16（not_comparable） |
| Segment revenue | Semiconductor and FPD Equipment Business ¥88,730 million (YoY +36.8%), Life Sciences Business ¥506 million (YoY +68.2%) |
| Segment profit | Semiconductor and FPD Equipment Business ¥26,388 million (YoY +61.8%), Life Sciences Business ¥-53 million |
| Regional sales | ¥8,327 million, ¥11,979 million, ¥34,548 million, ¥5,981 million, ¥23,372 million, ¥5,026 million |
| Orders received and order backlog | Orders received ¥81,562 million (YoY +135.7%) / Order backlog ¥62,652 million (YoY +102.4%) |
| Depreciation and amortization | ¥2,094 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥0 million / Extraordinary loss Loss on sale of fixed assets ¥0 million, Loss on Disposal of Fixed Assets ¥33 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 2 / Company name Nanoverse Technologies,Ltd., ジェノスタッフ株式会社 / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No (no eligible attendees) |
| Issued Shares at Period-End | 176,400,000 |
| Treasury Shares at Period-End | 42,860 |
| Factors Behind Changes in Business Performance | 半導体需要の回復と在庫の正常化が進む中、生成ＡＩ関連の先端半導体需要が中心となり、半導体需要の回復が進展した。中国では、自国のサプライチェーン強化を目指した半導体製造拠点の増強に伴い、中国向け装置需要が活発化した。 |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.半導体需要の回復と在庫の正常化、生成AI関連の先端半導体需要の拡大、中国での半導体製造拠点増強に伴う中国向け装置需要の活発化。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.